BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c
November 15, 2016 9:19 AM ESTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).
As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
... More